The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma
Official Title: A Pharmacokinetic Study of Methotrexate Using an Intratumoral Microdialysis Catheter
Study ID: NCT00463008
Brief Summary: RATIONALE: Collecting fluid from a brain tumor using a small catheter may help doctors learn how much methotrexate gets into the tumor to kill the tumor cells. It may also help doctors learn how methotrexate works in the brain and in the rest of the body. PURPOSE: This clinical trial is studying how much methotrexate gets into the brain tumor by collecting fluid directly from the tumor through a small catheter in patients undergoing stereotactic biopsy for recurrent high-grade glioma.
Detailed Description: OBJECTIVES: * Determine the feasibility of using microdialysis to study distribution of systemically administered methotrexate in the interstitial fluid within a tumor in patients undergoing stereotactic biopsy for recurrent high-grade gliomas. * Determine the systemic and intratumoral pharmacokinetics of this drug in these patients. OUTLINE: This is a multicenter study. Patients have an intratumoral microdialysis catheter placed while undergoing stereotactic biopsy. Between 18-32 hours after placement of catheter, patients receive methotrexate IV over 4 hours. Microdialysis perfusate and blood specimens are collected before, during, and for 24 hours after methotrexate administration. Patients are followed at 2 weeks. PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study within 6 months.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Name: Jeffrey J. Olson, MD
Affiliation: Emory University
Role: STUDY_CHAIR
Name: Stuart A. Grossman, MD
Affiliation: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Role: